Curanex Pharmaceuticals Inc
For the period ended Sep 30, 2025. Filed Nov 17, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 17, 2025
CURX$6.21+7.4%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| As of September 30, 2025 | As of December 31, 2024 | |
|---|---|---|
| (unaudited) | ||
| ASSETS | ||
| Current assets | ||
| Cash | $5,830,537 | $148,891 |
| Prepaid Expenses | 8,587,222 | 1,179 |
| Other Current Assets | - | 367,865 |
| Total current assets | 14,417,759 | 517,935 |
| Right-of-Use Asset | 60,398 | - |
| TOTAL ASSETS | 14,478,157 | 517,935 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accrued expenses | 10,316 | 9,575 |
| Accounts payable | 114,489 | 5,000 |
| Lease Liability, current | 61,150 | - |
| Total current liabilities | 185,955 | 14,575 |
| TOTAL LIABILITIES | 185,955 | 14,575 |
| Shareholders’ equity | ||
| Common stock, 475,000,000 shares authorized; $0.0001 par value; 28,340,812 shares issued and outstanding as of September 30, 2025, and 24,000,000 December 31, 2024 | 2,834 | 2,400 |
| Preferred stock, 25,000,000 shares authorized; $0.0001 par value; 1,000,000 shares issued and outstanding as of September 30, 2025, and December 31, 2024 | 100 | 100 |
| Common stock to be issued | - | 200,000 |
| Additional paid-in capital | 16,063,705 | 923,309 |
| Accumulated deficit | (1,774,437) | (622,449) |
| TOTAL SHAREHOLDERS’ EQUITY | 14,292,202 | 503,360 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $14,478,157 | $517,935 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.